

Consiglio Nazionale delle Ricerche


ISTITUTO DI BIOIMMAGINI E FISILOGIA MOLECOLARE (IBFM)



In-vitro and *in-vivo* radiobiological studies for
the comprehension of molecular radio-resistance
mechanisms by interdisciplinary approach

Giusi Forte

THE IBFM TRANSLATIONAL RESEARCH MODEL





26/02/2016

Radiobiology Knowhow

Biological effects induced by ionizing radiations are studied by *in-vitro*, *ex-vivo* and *in-vivo* approaches and by the integration of **multimultidisciplinary skills** of physicists, engineers, biologists and physicians.


The *in-vitro* activities have been conducted on **Breast cancer cells** with different beams:

- electrons,
- protons and
- electrons produced by laser target interaction



Istituto di Bioimmagini e Fisiologia
Molecolare (IBFM) - CNR




Biological Skills




Physics Skills

Geant4 Monte Carlo simulations


Dosimetry




IORT simulation



Laser-driven simulation



Catana simulation



Experimental Radiobiology

1. In vitro/ ex vivo cell-based models



Using different Breast Cancer cell lines:

- Immortalized:
 1. Tumorigenic: MCF7; MDA-MB-231
 2. Non tumorigenic: MCF10A
- Normal and tumour primary cells from patients biopsies

2. In vivo approach with mouse models




Work in progress:



- Ministry authorization
- Animal facility
- Dosimetry and simulation studies

1. In vitro/ ex vivo cell-based models

Main goal is to highlight molecular mechanisms involved in the response to Radiation Treatment with different types of beam, in order to identify radio-resistance biomarkers and personalize treatments.



IOERT Treatment with Linear Accelerator NRT Novac 7



BREAST CELL LINES

Immortalised cells:

- MCF7 (Lum.B, Er+/Pr+)
- MDA-MB-231 (Bas.B, Er-/Pr-)
- MCF10A (Bas.B, Er-/Pr-)

Normal and tumour primary cells



IOERT




2 Radiotherapy Treatments:

9 Gy (*boost*);

23 Gy



High-dose Ionizing Radiation Regulates Gene Expression Changes in the MCF7 Breast Cancer Cell Line.

Bravatà V¹, Minafra L¹, Russo G², Forte GI², Cammarata FP², Ripamonti M², Casarino C², Augello G³, Costantini F³, Barbieri G³, Messa C⁴, Gilardi MC⁵.



Gene Expression Profiling of MCF10A Breast Epithelial Cells Exposed to IOERT.


Minafra L¹, Bravatà V¹, Russo G², Forte GI², Cammarata FP², Ripamonti M², Candiano G², Cervello M³, Giallongo A³, Perconti G³, Messa C⁴, Gilardi MC⁵.




Morphology – Clonogenicity

DNA Damage (γ-H2AX Foci)


Different Radioresistance percentages to IOERT treatment in BCpc



RCF:58-55%



RCF:23-19%





RCF:10-5%



Personalized molecular models of response to treatments

Bravatà *et al*: Gene Expression Response of MCF7 Cells Following IOERT Treatment

Minafra *et al*: Gene Expression Profiling of MCF10A Exposed to IOERT



CANCER GENOMICS & PROTEOMICS 12: 143-152 (2015)



Transl Cancer Res 2014;3(1):32-47

Review

Di Maggio *et al*. *Journal of Inflammation* (2015) 12:14
DOI 10.1186/s12950-015-0058-3

Biological basis of IOERT

Cell and molecular response to IOERT treatment

Luigi Minafra*, Valerina Bravatà*

IBFM CNR-LATO, Cefalù (PA), Italy

*These authors contributed equally to this work.

Correspondence to: Luigi Minafra IBFM CNR-LATO, Cefalù (PA), Italy. Email: luigi.minafra@ibfm.cnr.it; Dr. Valerina Bravatà, IBFM CNR-LATO, Cefalù (PA), Italy. Email: valerina.bravata@ibfm.cnr.it

Caveolin-1, Breast Cancer and Ionizing Radiation

MARZIA PUCCI¹*, VALENTINA BRAVATÀ¹, GIUSI IRMA FORTE¹, FRANCESCO PAOLO CAMMARATA¹, CRISTINA MESSA^{1,2,3}, MARIA CARLA GILARDI^{1,2,4} and LUIGI MINAFRA^{1*}

¹Institute of Biomedicine and Molecular Physiology,

National Research Council (IBFM-CNR) - LATO, Cefalù (PA), Italy;

²Department of Health Sciences, Tecnomed Foundation, University of Milano-Bicocca, Milan, Italy;

³Nuclear Medicine Center, San Gerardo Hospital, Monza, Italy;

⁴Nuclear Medicine, San Raffaele Scientific Institute, Milan, Italy

REVIEW

Open Access

Portrait of inflammatory response to ionizing radiation treatment

Federica Maria Di Maggio^{1,2}, Luigi Minafra², Giusi Irma Forte², Francesco Paolo Cammarata², Domenico Lio¹, Cristina Messa^{2,3,4}, Maria Carla Gilardi^{2,3,5} and Valerina Bravatà^{2*}

Inflammatory profile of BC cell lines conditioned media treated with 9 e 23 Gy

Bio-Plex Pro™ Human Th17 Cytokine Panel 15-Plex





Figure 1 Schedule of irradiation and collection of CM and ICM




IL-1b, IL-6, TNF- α (proinflammation);
 IL-12 (p70), IFN- γ (TH1);
 IL-4, IL-5, IL-10, IL-13 (TH2);
 IL-8, MCP-1, MIP-1b (chemokines);
 IL-2, IL-7, IL-17, GM-CSF, G-CSF (immunomodulation);
 TGF- β 2, VEGFA (tissue modulating)

MCF7
 MDA-MB-231
 MCF10A


Cell lines



INO
ISTITUTO NAZIONALE
DI OTTICA



Esperimento elettroni Pisa. MCF7



Machine	cGy/pulse	pulse lifetime	Gy/sec for pulse
Clinical Linac (Novac7)	10	1,2 microSec	80
ILIL Accelerator	7	1 picoSec	70*10⁹





BREAST CELL LINES

Immortalised cells:

- MCF7 (Lum.B, Er+/Pr+)
- MDA-MB-231 (Bas.B, Er-/Pr-)
- MCF10A (Bas.B, Er-/Pr-)




Hadrotherapy (protons)

0,5 Gy, 2 Gy, 4 Gy, 6 Gy, 9 Gy

NEXT STEP:

In vitro studies allowed us to acquire knowledge in order to be able to plan *in vivo* studies.



PRECLINICAL HADRONTHERAPY TREATMENT



STUDIO IN "VIVO" DI TRATTAMENTI CON ADRONI DI TUMORE
MAMMARIO SU TOPI



"PETS" PRECLINICAL HADRONTHERAPY STUDIES




CATANA
facility @
INFN-LNS




POSITIONING SYSTEM

An important part of a hadrontherapy treatment is the positioning ...


Human positioning system



Small animal positioning system




Geant 4 SIMULATION




Geant4

Our custom application



Simulation results



Validation phase needed



Experimental results



FIRST PRECLINICAL TREATMENT




ETHICS



Pre-clinical *experimental* and *theoretical* studies to *improve* treatment and *protection* by *charged* particles

Understanding the underlying action mechanisms on normal cells by charged particles used in medicine to reduce the risks for human health



8.1.1. WP-1.1 Breast

- 8.1.1.1. DNA damage modelling
- 8.1.1.2. Molecular mechanisms and gene expression profile
- 8.1.1.3. Inflammatory profile and role of cytokines in normal cell response
- 8.1.1.4. Genetic and sub-lethal cellular damage

8.3. Detailed activity of WP-3: Pre-clinical studies

- 8.3.1. WP-3.1 Monte-Carlo simulations
- 8.3.2. WP-3.2 Realization of the experimental setup
- 8.3.3. WP-3.3 In vivo irradiations
- 8.3.4. WP-3 references

THANKS

THE RADIOBIOLOGY GROUP

IBFM-CNR

Francesco P. Cammarata
Giusi I. Forte
Luigi Minafra
Valentina Bravatà
Valentina Marchese
Giorgio Russo
Pietro Pisciotta
Debora Lamia

Maria Carla Gilardi



INFN/UNICT

G.A. Pablo Cirrone
Francesco Romano
Giacomo Candiano
Rosaria Acquaviva
Vincenzo Zimmitti
Marco Abate

Giacomo Cuttone



INO-CNR

Luca Labate
Federica Baffigi
Lorenzo Fulgentini
Petra Koester
Daniele Palla

Leonida Gizzi
Antonio Giulietti

